Skip to main content

Kidney Cancer


True or False: Older age, greater frailty, and having two or more comorbid conditions are associated with lower oral anticancer agent use for metastatic RCC.
Akram Mesleh Shayeb, MD, discusses results from a real-world study evaluating cabozantinib in combination with direct…
Guideline Updates
NCCN released an update to its clinical practice guideline for kidney cancer, featuring updates to first-line and…
Stephanie Wheeler, PhD, MPH, discusses results from a study focusing on patterns and predictors of oral anticancer…
Daniel Geynisman, MD, discusses treatment patterns and sequences in real-world patients with metastatic RCC after first…
Back to Top